Jiaqi Yuan

Sep 19, 2024 | dx.doi.org | Jiaqi Yuan |Hui Tan |Yue Huang |Anton I. Rosenbaum

IntroductionClick to copy section linkSection link copied!Over the past decades, antibody-drug conjugates (ADCs) have become an increasingly important therapeutic modality in the biopharmaceutical industry. Currently, there are 13 approved ADCs, and many more under evaluation in clinical trials. (1) ADCs are designed to improve therapeutic index (TI) by targeted payload delivery to increase efficacy and limit the payload off-target toxicity.

Sep 19, 2024 | pubs.acs.org | Jiaqi Yuan |Hui Tan |Yue Huang |Anton I. Rosenbaum

Analytical ChemistryCite this: Anal. Chem. 2024, XXXX, XXXClick to copy citationCitation copied!. This publication is licensed under CC-BY 4.0 . You are free to share (copy and redistribute) this article in any medium or format and to adapt (remix, transform, and build upon) the material for any purpose, even commercially within the parameters below:Creative Commons (CC): This is a Creative Commons license. Attribution (BY): Credit must be given to the creator.